Cancer research in NSW will get a further boost with the establishment of the Australian Cancer Research Foundation (ACRF) Tumour Metabolism Laboratory, supported by the Cancer Institute NSW.
The laboratory will help the work of Professor Philip Hogg and Sydney’s Centenary Institute to better understand how cancer cells metabolise dietary nutrients.
The goal is to provide critical information to the development of new diagnostics and therapies for people with cancer, focusing on endometrial, brain and breast tumours.
The Cancer Institute NSW is supporting the Centenary Institute by funding scientists to carry out the research, together with Australian Cancer Research Foundation (ACRF) who are contributing $2.5 million to establish the laboratory.
Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow, says the Institute is proud to be partnering with the ACRF in this exciting new initiative.
“The ACRF Tumour Metabolism Laboratory provides an opportunity to gain important new knowledge of changes at the molecular level of tumours,” he says.
“By supporting researchers working in the lab, we hope to accelerate these important discoveries.”
Turning research into treatment
For Professor Philip Hogg this announcement is the latest in what has been a career of leading cancer research.
It’s a career the Cancer Institute NSW is proud to be supporting, both in advancing potential treatments for people with cancer and retaining world class research in NSW.
As lead investigator, Professor Hogg’s team was awarded a 2006 Translation Program Grant from the Cancer Institute NSW, putting $3.75 million into funding the study of anti-mitochondrial cancer drugs.
The drugs involved in that research, GSAO and PENAO, have the power to shrink tumours and potentially provide an alternative to chemotherapy.
They’re attracting international interest and recognition, and the work has been called “ground-breaking” and “revolutionary”.
“GSAO and PENAO have now completed Phase 1 trials in patients with solid tumours in Australia and the United Kingdom,” Professor Hogg explains, talking in August this year.
“The molecules have been well tolerated and a safe dose for further trials has been determined.”
“A Phase 2 trial of PENAO in patients with kids and adults with brain tumours in Australia is in the planning stages.”
Speaking about cancer research in NSW, Professor Hogg says we're just starting to realise some of the benefits of the translational cancer research ongoing for the last ten years.
In 2009 Professor Hogg received the honour of NSW Outstanding Cancer Researcher of the Year from the Cancer Institute NSW, a culmination of his immense work.
He says this support, beyond his own role, is creating more research opportunities and changing cancer outcomes in NSW.
Building greater collaboration between researchers and clinicians, and implementing new research, brings new and exciting prospects for people with cancer.
Supporting cancer research in NSW is a key part of the NSW Cancer Plan, with work leading to the goal of increasing survival for people with cancer.